The United States Food and Drug Administration (FDA) approves pharmaceutical drugs for human use through the New Drug Application (NDA) 505 b (1) and 505 b (2) application process (US FDA). There are two routes for new drug approval established by law in the United States: the 505(b)(1) NDA pathway and the 505(b)(2) NDA pathway. For new drugs containing active ingredients that have not yet been approved, the 505(b)(1) NDA pathway is used to gain approval. All relevant safety and efficacy data should be included in an NDA application submitted via this route. Applications submitted under the 505(b)(2) NDA Regulatory pathway are subject to additional requirements, including the submission of full reports of safety and effectiveness investigations and the use of data from studies that the applicant did not conduct and for which the applicant did not obtain a right of reference. For drugs that have already been evaluated and approved by the FDA as part of other NDAs, the 505(b)(2) New Drug Application route is used for applications with changes in dosage form, change in strength, and change in route of administration.
Most sponsors struggle to figure out how to navigate the FDA’s rules, which regulatory pathway to take for their drug development case, and what regulatory strategy to employ when submitting an NDA. The sponsor of an NDA must include all information required by Federal Regulations. Suppose the sponsor does not provide sufficient data. In that case, the US Food and Drug Administration (FDA) may Refuse to File (RTF) the NDA, making further development impossible unless the sponsor provides data to satisfy FDA’s requirements. Sponsors can save time and money (in the form of the agency fee) by simply being familiar with the NDA filing process and the guidance outlining the reasons for RTF of a New Drug Application.
From the initial pre-NDA meetings through the submission of annual reports and beyond, E&E Medicals provides comprehensive Regulatory support to the sponsors throughout the entire NDA process.